L-ASPARAGINASA EFECTOS ADVERSOS PDF
Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.
|Published (Last):||17 September 2016|
|PDF File Size:||6.16 Mb|
|ePub File Size:||11.90 Mb|
|Price:||Free* [*Free Regsitration Required]|
For agents that have known adverse events occurring beyond 7 days after administration, this period must l-wsparaginasa extended beyond the time during which adverse events are known to occur. A l-aeparaginasa of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells.
Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible. EU Clinical Trials Register. Clear advanced search filters. Restricciones de tratamientos previos: Known allergy to any of the drugs used in the study.
Active treatment for graft-versus-host disease 6. Subjects must have a serum creatinine level that is?
Review by the Competent Authority or Ethics Committee in the country concerned. Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy?
Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc. Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.
Weight Management Health Library, Free Bariatric Surgery Videos, Learn About Food, Nutrion, Diet
Committee on Advanced therapies CAT has issued a classification for this product. Title of the trial for lay people, in easily understood, i. Age 18 years or younger at the time of study treatment initiation. For these items efecos should use the filters and not add them to your search terms in the text field.
l-asparaginasa efectos adversos pdf
Combination product that includes a device, but does not involve an Advanced Therapy. How to search [pdf].
The duration of this interval must be approved by the Onyx study medical monitor. The trial involves single site in the Member State concerned. Trials with results Trials without results. Plans for treatment or care after the subject has adveersos the participation in the trial if it is different from the expected normal treatment of that condition.
l-asparaginasa efectos adversos pdf – PDF Files
The IMP has been designated in this indication as an orphan drug in the Community. Both Female Only Male Only. Definition of the end of the trial and l-asparwginasa where it is not the last visit of the last subject undergoing the trial. Date on which this record was first entered in the EudraCT database:.
Cancer AND drug name. Relapsed or Refractory Acute Lymphoblastic Leukemia.
Trials with results Trials without results Clear advanced search filters. IMP with orphan designation in the indication. Subjects are under 18 years old.
Pneumonia AND sponsor name. Karnofsky or Lansky scores? Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7. Adequate liver function, defined as both of the following: Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p.